Oral lipid formulation type IV as an approach in the formulation of solid dosage forms with poorly soluble substances: Chremophor®RH 40 as a surfactant phase

Main Article Content

Tanja Vojinović
Jelena Djuris
Zorica Potpara
Svetlana Ibric


Gliclazide; Cremophor®RH40; Oral solid lipid formulations; Neusilin®UFL2


Aim of this study was investigation into solid oral lipid formulations with poorly soluble substance gliclazide, using non-ionic surfactant Cremophor®RH40. The use of a new approach to the formulation of type IV of solid oral lipid formulations is described. Drug/surfactant solution was adsorbed on magnesium-aluminium metasilicate (Neusilin®UFL2) carrier with or without addition of superdisintegrant and filled into hard gelatin capsules or compressed into tablets. In this way, a very fast and complete dissolution of poorly soluble drug is achieved. This study shown that with proper selection of ratio of drug/surfactant/adsorbent, with or without superdisintegrant in formulation, it is possible to achieve rapid dissolving of poorly soluble drug from solid dosage forms.


Download data is not yet available.
Abstract 559 | PDF Downloads 313


[1] Mathavan S, Chen-Tan N, Arfuso F, Al-Salami H. The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes. Artif Cells Nanomed Biotechnol 2016;44(6):1508-19.

[2] Colin W, Pouton C.W, Christopher J.H. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv Drug Deliver Rev 2008; 60:625–637.

[3] Pouton C.W. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006; 29: 278–287.

[4] Strickley R.G, in: D.J. Hauss (Ed.). Oral lipid-based formulations: enhancing the bioavailability of poorly water soluble drugs. Informa Healthcare New York 2007; pp. 1–31.

[5] Ewart T.C, Dominique C, Hassan B. Challenges and Opportunities in The Encapsulation of Liquid and Semi-Solid Formulations into Capsules for Oral Administration. Adv Drug Deliver Rev 2008; 60:747-756.

[6] Bowtle W.J, in: D.J. Hauss (Ed.). Oral Lipid-Based Formulations - Enhancing the Bioavailability of Poorly Water-Soluble Drugs. Informa Healthcare New York 2007; pp. 79–106.

[7] Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliver Rev 2008; 60:734 – 746.

[8] Wang S. Ordered mesoporous materials for drug delivery. Micropor Mesopor Mat 2009; 117: 1–9.